Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reolysin with or without GM-CSF in Advanced Melanoma
NCT03282188Phase 2Withdrawn
- Sponsor
- University of Leeds
- Start
- Oct 2017
- Primary completion
- Jul 2018
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of pelareorep in melanoma (2 arms), sponsored by University of Leeds. Primary endpoint: Reovirus tumor infiltration by immunohistochemistry at 18 months. Planned start Oct 2017; status: withdrawn.
02
Drugs
pelareorep
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03282188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03282188.